Cite
HARVARD Citation
Rosell, R. et al. (2017). Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial. Lancet. 5 (5), pp. 435-444. [Online].